Amphastar Pharmaceuticals
AMPH
276 hedge funds and large institutions have $2.16B invested in Amphastar Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 97 increasing their positions, 93 reducing their positions, and 24 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
100% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 24
53% more call options, than puts
Call options by funds: $3.35M | Put options by funds: $2.18M
47% more capital invested
Capital invested by funds: $1.47B → $2.16B (+$692M)
8% more funds holding
Funds holding: 255 → 276 (+21)
7.53% more ownership
Funds ownership: 65.5% → 73.03% (+7.5%)
4% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 93
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
+$99.7M |
| 2 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$34.1M |
| 3 |
EIP
Epoch Investment Partners
New York
|
+$24.2M |
| 4 |
BCM
Boone Capital Management
Atlanta,
Georgia
|
+$21M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$28.8M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$18.2M |
| 3 |
Goldman Sachs
New York
|
-$9.64M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$8.9M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$8.62M |
AMPH Hedge Fund Activity: Q4 2023 in Review
276 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q4 2023, worth a combined $2.16B — up 47% from $1.47B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new AMPH positions and 24 closed out — a net gain of 24 holders — while 97 added to existing stakes and 93 trimmed.
The largest buyer was Neuberger Berman Group, adding an estimated $99.7M. The largest seller was Dimensional Fund Advisors, cutting an estimated $28.8M.
- 276 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q4 2023, up from 255 in Q3 2023.
- Funds reported $2.16B of Amphastar Pharmaceuticals stock for Q4 2023, up 47% quarter-over-quarter.
- 48 funds opened new Amphastar Pharmaceuticals positions in Q4 2023 and 24 closed out, a net change of +24 holders.
- The largest Amphastar Pharmaceuticals buyer in Q4 2023 was Neuberger Berman Group, an estimated $99.7M added.
- The largest Amphastar Pharmaceuticals seller in Q4 2023 was Dimensional Fund Advisors, an estimated $28.8M sold.
Based on aggregated 13F filings for Q4 2023.